These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 7813550)

  • 21. 5-hydroxytryptamine (5-HT)1A receptors and the tail-flick response. I. 8-hydroxy-2-(di-n-propylamino) tetralin HBr-induced spontaneous tail-flicks in the rat as an in vivo model of 5-HT1A receptor-mediated activity.
    Millan MJ; Bervoets K; Colpaert FC
    J Pharmacol Exp Ther; 1991 Mar; 256(3):973-82. PubMed ID: 1826033
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A behavioural and biochemical study in mice and rats of putative selective agonists and antagonists for 5-HT1 and 5-HT2 receptors.
    Goodwin GM; Green AR
    Br J Pharmacol; 1985 Mar; 84(3):743-53. PubMed ID: 2580582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of the aliphatic spacer length on the 5-HT1A receptor activity of new arylpiperazines with an indazole system.
    Paluchowska MH; Duszyńska B; Kłodzińska A; Tatarczyńska E
    Pol J Pharmacol; 2000; 52(3):209-16. PubMed ID: 11055578
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biochemical, electrophysiological and neurohormonal studies with B-20991, a selective 5-HT1A receptor agonist.
    Caicoya AG; Beneytez ME; Delgado M; Manzanares J; López-Rodríguez ML; Benhamu B; Morcillo MJ; Pozo MA; Rubia FJ; Fuentes JA
    Pharmacology; 2001 May; 62(4):234-42. PubMed ID: 11360001
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of the 5-HT1A receptor involvement in passive avoidance in the rat.
    Misane I; Johansson C; Ogren SO
    Br J Pharmacol; 1998 Oct; 125(3):499-509. PubMed ID: 9806333
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel class of arylpiperazines containing N-acylated amino acids: their synthesis, 5-HT1A, 5-HT2A receptor affinity, and in vivo pharmacological evaluation.
    Zajdel P; Subra G; Bojarski AJ; Duszyńska B; Tatarczyńska E; Nikiforuk A; Chojnacka-Wójcik E; Pawłowski M; Martinez J
    Bioorg Med Chem; 2007 Apr; 15(8):2907-19. PubMed ID: 17321139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological characterization of LB50016, N-(4-amino)butyl 3-phenylpyrrolidine derivative, as a new 5-HT1A receptor agonist.
    Lee CH; Oh JI; Park HD; Kim HJ; Park TK; Kim JS; Hong CY; Lee SJ; Ahn KH; Kim YZ
    Arch Pharm Res; 1999 Apr; 22(2):157-64. PubMed ID: 10230506
    [TBL] [Abstract][Full Text] [Related]  

  • 28. 5-HT1A and muscarinic acetylcholine receptors jointly regulate passive avoidance behavior.
    Riekkinen P
    Eur J Pharmacol; 1994 Sep; 262(1-2):77-90. PubMed ID: 7813581
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis, 5-HT1A and 5-HT2A receptor activity of new 1-phenylpiperazinylpropyl derivatives with arylalkyl substituents in position 7 of purine-2,6-dione.
    Chloń G; Pawłowski M; Duszyńska B; Szaro A; Tatarczńska E; Kłodzińska AL; Chojnacka-Wójcik E
    Pol J Pharmacol; 2001; 53(4):359-68. PubMed ID: 11990082
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the brain-penetrant and selective 5-HT6 receptor antagonist SB-399885 in animal models of anxiety and depression.
    Wesołowska A; Nikiforuk A
    Neuropharmacology; 2007 Apr; 52(5):1274-83. PubMed ID: 17320917
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The corticosterone-enhancing effects of the 5-HT1A receptor antagonist, (S)-UH301, are not mediated by the 5-HT1A receptor.
    Groenink L; Van der Gugten J; Mos J; Maes RA; Olivier B
    Eur J Pharmacol; 1995 Jan; 272(2-3):177-83. PubMed ID: 7713161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neuronal circuits involved in the anxiolytic effects of the 5-HT1A receptor agonists 8-OH-DPAT ipsapirone and buspirone in the rat.
    Schreiber R; De Vry J
    Eur J Pharmacol; 1993 Nov; 249(3):341-51. PubMed ID: 7904566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic responses to 5-HT1A or 5-HT2A/2C receptor activation is differentially regulated in four regions of rat brain.
    Tilakaratne N; Friedman E
    Eur J Pharmacol; 1996 Jun; 307(2):211-7. PubMed ID: 8832223
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of hypothermia as a model of 5-hydroxytryptamine1A receptor-mediated activity in the rat: a pharmacological characterization of the actions of novel agonists and antagonists.
    Millan MJ; Rivet JM; Canton H; Le Marouille-Girardon S; Gobert A
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1364-76. PubMed ID: 8450471
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 2-H- and 2-acyl-9- [omega-[4-(2-methoxyphenyl)piperazinyl]-alkyl]-1,2,3,4-tetrahydro-beta-carbolines as ligands of 5-HT1A and 5-HT2A receptors.
    Boksa J; Mokrosz MJ; Charakchieva-Minol S; Tatarczyńska E; Kłodzińska A; Wesołowska A; Misztal S
    Pol J Pharmacol; 2001; 53(5):501-8. PubMed ID: 11990069
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical pharmacology of B-20991, a 5-HT1A receptor agonist with anxiolytic activity.
    Beneytez ME; López Rodríguez ML; Rosado ML; Morcillo MJ; Orensanz L; Fuentes JA; Manzanares J
    Eur J Pharmacol; 1998 Mar; 344(2-3):127-35. PubMed ID: 9600646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct injection of 5-HT2A receptor agonists into the medial prefrontal cortex produces a head-twitch response in rats.
    Willins DL; Meltzer HY
    J Pharmacol Exp Ther; 1997 Aug; 282(2):699-706. PubMed ID: 9262333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Differential efficacy of serotonergic drugs FG5974, FG5893, and amperozide in reducing alcohol drinking in P rats.
    Lankford MF; Björk AK; Myers RD
    Alcohol; 1996; 13(4):399-404. PubMed ID: 8836330
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New methoxy-chroman derivatives, 4[N-(5-methoxy-chroman-3-yl)N- propylamino]butyl-8-azaspiro-(4,5)-decane-7,9-dione [(+/-)-S 20244] and its enantiomers, (+)-S 20499 and (-)-S 20500, with potent agonist properties at central 5-hydroxytryptamine1A receptors.
    Kidd EJ; Haj-Dahmane S; Jolas T; Lanfumey L; Fattaccini CM; Guardiola-Lemaitre B; Gozlan H; Hamon M
    J Pharmacol Exp Ther; 1993 Feb; 264(2):863-72. PubMed ID: 8094756
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Further investigation of the in vivo pharmacological properties of the putative 5-HT1A antagonist, BMY 7378.
    Sharp T; Backus LI; Hjorth S; Bramwell SR; Grahame-Smith DG
    Eur J Pharmacol; 1990 Feb; 176(3):331-40. PubMed ID: 1970304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.